Next-gen digital health innovation in clinical trials

The Next Horizon of Digital Clinical Trials

Digital transformation of clinical trials is already underway. Rather than doing the same things more efficiently vanguard companies are looking for ways to use technology to do things differently. Some of these solutions are right around the corner, while others are further off. Below are some of the most exciting developments we are tracking in the space:

  • Replace traditional control arms with synthetic control arms or digital twins
    Traditionally, control groups in randomized controlled trials will receive a placebo or the current therapy considered standard-of-care to serve as a comparison for the intervention under investigation. However, the use of traditional control groups has raised ethical questions especially for debilitating conditions such as cancer or rare disease, or when the standard of care has limited efficacy. One alternative is synthetic control arms which use historic data or real-world evidence as opposed to traditional control arms. One digital health startup, UnlearnAI, is taking the idea a step further with their machine learning platform DiGenesis that builds “digital twins.” In this context, digital twins are comprehensive, longitudinal, and computationally generated clinical records that describe what would have happened if a patient had received a placebo.

Enter your email address to download paper.

Click the link to begin download.
Oops! Something went wrong while submitting the form.

Enter your email address to watch the webinar.

Click the link to watch webinar.
Oops! Something went wrong while submitting the form.
Webinars

Applying Machine Learning to Increase Clinical Trial Efficiency: A Regulatory Journey

Press

Unlearn Closes $50 Million Series B Funding to Advance the Use of Its Machine Learning-Powered TwinRCTs™ in Clinical Trials

Press

Unlearn Signs Multi-Year Collaboration with Merck KGaA, Darmstadt, Germany to Accelerate Immunology Trials using Twintelligent RCTs™

Collaborators will leverage AI-generated Digital Twins to enable smaller, more efficient pivotal clinical trials.
Led by Insight Partners, financing builds on the company’s momentum in working with leading biopharmaceutical companies to improve clinical trial efficiency.
Learn about the evolution of ideas that led to our TwinRCT™ solution for smaller, more efficient clinical trials and recent EMA draft qualification opinion.